Guest Speaker: Management of Ocular injury in the ER setting
Diabetic retinopathy: Diagnosis and treatment
The aging eyes
Publications: Su, J.; Garcia, C.A. M.D.; Chu, H.H. M.D.; “Retinal Pigmented Epithelium Transplantation” University of Texas Medical School Research Abstract. p.29, 1990
Su, J. M.D.; Steidl, S. M.D.; Liu, S. M.D.; Gupta, P. M.D.; “Inhibition of Intraocular Fibrin Formation During Vitrectomy Following Infusion of Desmopressin” ARVO, 1997
Liu, S. M.D.; Su, J. M.D.; Hemady, R. M.D.; “ Corneal Melting after Avulsion of a Molteno Shunt Plate” J. Glaucoma, Vol 6, No. 6: 357-358, 1997
Liu, S. M.D.; Su, J. M.D.; Steidl, S. M.D.; Gupta, P. M.D.; “Inhibition of Postvitrectomy Fibrin Using Troxerutin” Retina, Vol 18, No. 3, 1998
Clinical Research:Sub-Investigator – A Phase 3 B, Randomized, Active Controlled, Double-Masked, Single Dummy, Multi-Center Comparative Trial, In Parallel Groups, To Compare The Safety and Efficacy of Intravitreous Injections of Macugen Given Every 6 Weeks For 54 Weeks (To Be Extended To 102 Weeks As Indicated) Plus Sham Photodynamic Therapy (PDT), To Macugen Plus PDT With Visudyne, In Subjects With Predominantly Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Protocol EOP1012. Version Date 28 August 2006. Study Closed. Sub-Investigator – A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Dose-Finding Trial, in Parallel of Groups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3, 0.03 or 0.003mg Pegaptanib Sodium (Macugen), Given as often as Every 6 Weeks for 3 years, to Sham Injections, in Subjects with Diabetic Macular Edema (DME) Involving the Center of the Macula. Protocol EOP1013. Version Date 11 December 2006. Study Closed.
Sub-Investigator – A Phase IV, Open-label, Multi-center Trial of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects with Subfoveal Neovascular Age-related Macular Degeneration (AMD) Initially Treated with a Different Modality Resulting in Maculopathy Improvement. Protocol EOP1023. Version Date 22 May 2006.
Sub-Investigator –A Trial to Assess the safety and Tolerability of repeated Doses of Intravitreal Administration of Two VEGF Trap Formulations in Subjects with Neovascular Age-Related Macular Degeneration. Protocol VGFT-OD-0603.
Sub-Investigator–A Phase III, Double-Masked, Multi-Center, Randomized, Sham-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus. Protocol FVF4170g.
Sub-Investigator – A Phase 3 B, Multicenter Study to Evaluate the Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD). Protocol FVF3689g. Version Date 16 February 2006. Study Closed.
Sub-Investigator – A Randomized, Double-Masked, Parallel Group, Multicenter, Dose-Finding Comparison of the Safety and Efficacy and ASI-001A 0.5 μg/day and ASI-001B 0.2 μg/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema. Protocol C-01-05-001.Version Date 5 March 2007. Enrollment Closed.
Sub-Investigator – A Mutlicenter, Randomized, Placebo-Controlled, Double-Masked, Parallel-Group, Dose-Ranging Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy: The MIVI III (Microplasmin For Vitreous Injection III) Trial. Protocol TG-MV-003. Version Date 16 May 2007.
Sub- Investigator-A Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion. Version 3.1. Dated 26 October 2005. Enrollment Closed
Sub- Investigator- A 52-Week, Masked, Multicenter, Randomized, Controlled Trial (With Up to 13 Weeks Additional Follow-up) to Assess the Safety and Efficacy of 700 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in Combination with Laser Photocoagulation Compared with Laser Photocoagulation Alone in the Treatment of Subjects with Diffuse Diabetic Macular Edema (DME). Protocol Number 206207-012-00.
Sub- Investigator- A Phase 1 single ascending dose trial to establish the safety, tolerability and pharmacokinetic profile of intravitreous injections of E10030 (anti-PDGF pegylated aptamer) monotherapy and of E10030 given in combination with Lucentis® 0.5 mg/eye in subjects with neovascular age-related macular degeneration. Protocol OPH1000.
Sub- Investigator – A Phase 1, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of iCo-007 Intravitreal Injection in Subjects with Diffuse Diabetic Macular Edema. 2006-007-01-DME. Active.
Principal Investigator – Injectable Ophthalmic Emulsion For Use in the Treatment of Macular Edema a Phase I, Open-label, Dose-Escalation Clinical Study to Assess the Safety and Tolerability in Patients with Diabetic Macular Edema Secondary to Diabetic Retinopathy.
Licensed: Texas and Maryland
Certification: Board Certified: American Board of Ophthalmology
Organizations: Fellow of American Academy of Ophthalmology